Quest Diagnostics Incorporated – Consensus Indicates 18.2% Upside Potential

Quest Diagnostics Incorporated found using the ticker (DGX) now have 15 total analysts covering the stock. The consensus rating is “Buy”. The range between the high target price and the low target price is between 185 and 129, with the middle target price at 156.4. Given that the stock’s previous close was at 132.37, this would imply an upside potential of 18.2%. There is a 50 day moving average of 151.49 and the 200 day moving average is 144.39. The company has a market cap of $15,505 million. Company website:

The potential market capitalization would be $18,319 million based on market consensus.

You can now share it on Stocktwits, just click on the logo below and add the ticker in the text to be seen.

Quest Diagnostics Incorporated provides diagnostic testing, information, and service in the United States and around the world. The Company develops and provides diagnostic information services, such as routine testing, non-routine and advanced clinical testing, pathology testing and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as the AmeriPath, Dermpath Diagnostics, ExamOne and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contracting entities and responsible care. organizations through a network of laboratories, patient service centers, phlebotomists in doctors’ offices, call centers and mobile paramedics, nurses and other healthcare professionals and well-being. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians with robust computing solutions. Quest Diagnostics Incorporated was founded in 1967 and is based in Secaucus, New Jersey.

Comments are closed.